WALVAX(SZ:300142) Ge Long Hui A P P·2025-08-03 08:33Core Viewpoint - Watson Bio (300142.SZ) has announced that its mRNA vaccine for respiratory syncytial virus, developed in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, has been accepted for clinical trial application by the National Medical Products Administration [1] Group 1 - The mRNA vaccine is based on an independently developed "mRNA vaccine technology platform" aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus infection [1] - Currently, there are no approved vaccines for this indication in China, while three have been approved overseas [1] - The acceptance of the clinical trial application will require further approval before clinical trials can commence, and it is not expected to have a significant impact on the company's operating performance for the current year [1]